Every material Form 8-K MBX Biosciences, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
MBX Biosciences reported a third-quarter 2026 net loss of $62.4 million, up from $21.6 million a year earlier, as research and development and general and administrative expenses both rose sharply. The company said cash, cash equivalents and marketable securities were $481.6 million at September 30, 2026, which it expects to fund operations into 2029, and the filing notes that $20.8 million of the G&A increase was stock-based compensation tied to modified awards for its former chief executive officer.
Net loss was $62.4 million, or $1.29 per share, for the quarter ended September 30, 2026, versus $21.6 million, or $0.63 per share, a year earlier.
R&D expenses rose to $32.0 million from $19.3 million, driven in part by start-up costs for the canvuparatide Phase 3 trial, which started in the third quarter.
G&A expenses rose to $34.3 million from $4.7 million, including $20.8 million of stock-based compensation tied to modified awards for the former CEO.
Cash, cash equivalents and marketable securities were $481.6 million, including $97.6 million net proceeds from at-the-market stock sales.
MBX Biosciences appointed Peter Radovich to its board of directors effective October 20, 2026, and the board set its size at eight directors. The filing says Mr. Radovich is independent under Nasdaq listing standards and will receive standard non-employee director compensation, including a stock option for 18,200 shares.
Peter Radovich appointed director effective October 20, 2026, as a Class I director serving until the 2028 Annual Meeting of Stockholders
Board size set at eight directors
Initial non-qualified stock option to purchase 18,200 shares, granted on the appointment date, plus cash compensation under the non-employee director policy
Company is entering into an indemnification agreement with Mr. Radovich in the same form as its other directors
MBX Biosciences said it has dosed the first patient in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for chronic hypoparathyroidism. The trial is planned to enroll approximately 160 adults and is a step toward potential registration of the drug candidate, though the filing reports no financial results or regulatory approval.
First patient dosed in the Phase 3 oPTimize trial, announced August 27, 2026
Trial plans to enroll approximately 160 adults, randomized 3:1 to canvuparatide or placebo over a 26-week double-blind period
Primary endpoint is a composite responder measure at Week 26, followed by a 78-week open-label extension
Trial is registered as NCT07699471 on clinicaltrials.gov
MBX Biosciences reported a second-quarter 2026 net loss of $37.1 million, up from $19.4 million a year earlier, as research and development and general and administrative expenses rose. The company said its $418.6 million in cash and investments is expected to fund operations into 2029, and it reiterated timelines for a Phase 3 start in Q3 2026 and Phase 1 data for MBX 4291 in Q4 2026.
Q2 2026 net loss was $37.1 million, or $0.78 per share, versus a net loss of $19.4 million, or $0.58 per share, in Q2 2025.
R&D expenses were $31.0 million versus $17.7 million; G&A expenses were $9.9 million versus $4.1 million.
Cash, cash equivalents and marketable securities were $418.6 million as of June 30, 2026, expected to last into 2029.
Steve Hoerter was appointed Chairman and Chief Executive Officer, succeeding Kent Hawryluk; John Smither was named Chief Financial Officer.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MBX Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →